These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32900604)

  • 21. How oncologists communicate information to women with recurrent ovarian cancer in the context of treatment decision making in the medical encounter.
    Elit LM; Charles C; Gafni A; Ranford J; Tedford-Gold S; Gold I
    Health Expect; 2015 Oct; 18(5):1066-80. PubMed ID: 23663240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.
    Geffen DB; Abu-Ghanem S; Sion-Vardy N; Braunstein R; Tokar M; Ariad S; Delgado B; Bayme M; Koretz M
    Ann Oncol; 2011 Nov; 22(11):2381-2386. PubMed ID: 21363879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of 21-gene recurrence score on chemotherapy decisions for patients with estrogen receptor-positive, epidermal growth factor receptor 2-negative and lymph node-negative early stage-breast cancer].
    Mao Y; Chen XS; Liang Y; Wu JY; Huang O; Zong Y; Fang Q; He JR; Zhu L; Chen WG; Li YF; Lin L; Fei XC; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):502-508. PubMed ID: 28728295
    [No Abstract]   [Full Text] [Related]  

  • 24. Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.
    Fallowfield L; Matthews L; May S; Jenkins V; Bloomfield D
    Psychooncology; 2018 Apr; 27(4):1264-1269. PubMed ID: 29448311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.
    Zhou P; Zhang WW; Bao Y; Wang J; Lian CL; He ZY; Wu SG
    Breast; 2020 Dec; 54():319-327. PubMed ID: 33278648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists.
    Rocque GB; Rasool A; Williams BR; Wallace AS; Niranjan SJ; Halilova KI; Turkman YE; Ingram SA; Williams CP; Forero-Torres A; Smith T; Bhatia S; Knight SJ
    Oncologist; 2019 Oct; 24(10):1313-1321. PubMed ID: 30872466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling patient-centered communication: oncologist relational communication and patient communication involvement in breast cancer adjuvant therapy decision-making.
    Step MM; Rose JH; Albert JM; Cheruvu VK; Siminoff LA
    Patient Educ Couns; 2009 Dec; 77(3):369-78. PubMed ID: 19811883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncologist-patient-caregiver decision-making discussions in the context of advanced cancer in an Asian setting.
    Malhotra C; Kanesvaran R; Barr Kumarakulasinghe N; Tan SH; Xiang L; Tulsky JA; Pollak KI
    Health Expect; 2020 Feb; 23(1):220-228. PubMed ID: 31682064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage.
    Yu-Qing Y; Lei W; Mei-Ling H; Jing-Jing X; Mei-Chen W; Jiang W; Jun-Sheng H; Rui L; Nan-Lin L
    Exp Mol Pathol; 2019 Jun; 108():150-155. PubMed ID: 31026440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
    Zipkin R; Schaefer A; Chamberlin M; Onega T; O'Malley AJ; Moen EL
    Cancer Med; 2021 Feb; 10(4):1253-1263. PubMed ID: 33455068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncologist, patient, and companion questions during pretreatment consultations about adjuvant cancer treatment: a shared decision-making perspective.
    Pieterse AH; Kunneman M; Engelhardt EG; Brouwer NJ; Kroep JR; Marijnen CAM; Stiggelbout AM; Smets EMA
    Psychooncology; 2017 Jul; 26(7):943-950. PubMed ID: 27502561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 21-Gene Recurrence Score Testing in HER2-positive Patients.
    Altman AM; Marmor S; Tuttle TM; Hui JYC
    Clin Breast Cancer; 2019 Apr; 19(2):126-130. PubMed ID: 30595493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
    Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
    Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant chemotherapy in elderly women with breast cancer: patients' perspectives on information giving and decision making.
    Harder H; Ballinger R; Langridge C; Ring A; Fallowfield LJ
    Psychooncology; 2013 Dec; 22(12):2729-35. PubMed ID: 23813806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shared decision making about palliative chemotherapy: A qualitative observation of talk about patients' preferences.
    Henselmans I; Van Laarhoven HW; Van der Vloodt J; De Haes HC; Smets EM
    Palliat Med; 2017 Jul; 31(7):625-633. PubMed ID: 28618897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Does a Shared Decision-Making (SDM) Intervention for Oncologists Affect Participation Style and Preference Matching in Patients with Breast and Colon Cancer?
    Bieber C; Nicolai J; Gschwendtner K; Müller N; Reuter K; Buchholz A; Kallinowski B; Härter M; Eich W
    J Cancer Educ; 2018 Jun; 33(3):708-715. PubMed ID: 27966192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Key Elements of Mammography Shared Decision-Making: a Scoping Review of the Literature.
    DuBenske LL; Schrager SB; Hitchcock ME; Kane AK; Little TA; McDowell HE; Burnside ES
    J Gen Intern Med; 2018 Oct; 33(10):1805-1814. PubMed ID: 30030738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.
    Zeng Y; Li Q; Qin T; Li S; Jin L; Wu J; Chen K; Deng H; Rao N; Liu Q; Su F; Jia W; Yao H
    Anticancer Res; 2017 Aug; 37(8):4539-4547. PubMed ID: 28739750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.